|
|
GLA-AF |
|
Vaxjo ID |
160 |
|
Vaccine Adjuvant Name |
GLA-AF |
|
Adjuvant VO ID |
VO_0005424
|
|
Description |
aqueous formulation (AF) of a chemically synthesized toll-like receptor (TLR) 4 agonist, glucopyranosyl lipid adjuvant (GLA) |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
GLA; 100 nM particles and the synthetic surfactant DPPC (dipalmitoylphosphatidylcholine) |
|
Storage |
2-8C |
|
Preparation |
aqueous formation |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 4 (TLR4). Induces Th1-biased immune profile. innate immune activation, Enhances granzyme B and IL-6 production in PBMCs from adults >60 years old in response to influenza antigen |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=66]
Clegg et al., 2014: Clegg CH, Roque R, Perrone LA, Rininger JA, Bowen R, Reed SG. GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza. PloS one. 2014; 9(2); e88979. [PubMed: 24551202].
Stephens and Varga, 2021: Stephens LM, Varga SM. Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population. Vaccines. 2021; 9(6); . [PubMed: 34207770].
|
|
